More recently, immune-oncology therapies, mainly immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway, have become the recommended first- and second-line treatments in Europe and North America for patients with advanced NSCLC [42, 43]. Here, CD274 is linked to non-small cell lung carcinoma.